• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
166386 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
$ b9 r+ x4 {! g8 |7 y2 T5 d! V
可以,但要有针对性,
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  ; J5 v' _+ n6 o) R! U3 v
; e2 }4 V3 H! U6 J
! n: ^8 @3 @: J; v/ n- ]# I- C& a0 S
Sub-category:5 @( X8 R0 m! m( I  @& n3 h
Molecular Targets
8 [( s4 h! m# F: K+ U# w3 N% d% ^1 D5 g5 f3 ]
# x6 o0 E' j) Z1 _: p
Category:
# F) w0 |  x; S9 V8 xTumor Biology
5 t8 r! `6 {, C: L8 f0 R' I1 f$ i5 C/ d7 M4 h, Y
5 ?! K8 C4 |' k
Meeting:
0 s# q4 l6 l1 e. H* i: u5 Y2011 ASCO Annual Meeting 2 d$ q0 g( C* j; v: l, |6 @' ~

9 z/ i/ m7 I- s6 ~, r1 @. E6 @" r, c& n% S4 b
Session Type and Session Title:
9 L: k( A+ T' ]8 N3 ~! k7 F( [Poster Discussion Session, Tumor Biology
- B1 f) t6 k7 O7 @+ M# {0 `" Z7 w6 p7 \
$ J( X4 [0 a- Z% c
Abstract No:( l1 i& M! h1 L6 B
10517 ( M; y# }9 \/ d) F5 f2 o5 ~$ B
6 s; O. C; p# s4 A: K

1 ^2 b& T# D4 _* y# qCitation:
$ `4 o0 ?+ g: w$ d8 LJ Clin Oncol 29: 2011 (suppl; abstr 10517)
2 C+ k5 U' D9 B# h% K0 J5 _# ], H" |% d% F4 X% d( N! W
; n; W2 W! M/ B5 f4 h1 e) N1 G9 \
Author(s):
& k- P9 \9 P4 W) M0 i- kJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China . \% A5 C8 |- C% ~

6 h  y, u. n6 \0 o' q2 ?
8 P3 Y, [4 \* c, N/ }6 Q) j7 V0 s  o( @
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.: w' `0 x( N- e! X6 G5 P
0 \- I; ^; s6 v" u5 V! L
Abstract Disclosures! Z8 x9 u; K& o: B

! `9 W9 P6 R- e2 u; U4 h2 nAbstract:
' }( s4 j. X0 U* E2 S& @9 X4 u+ s1 q) x' w

. l5 ?" k2 C2 R# w0 zBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
/ L3 a6 O; d, ?# k* F0 |- L, T6 c) w* r

: C2 V3 T" C$ x, y% E5 y$ \
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
2 ]8 p% P) X( i' q8 ~" r没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
$ @, C9 F1 n+ K' B' t% i
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
: j7 {2 u# y" E; ~; \$ I& u易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。5 Z! o# [+ d8 Z, @9 H
ALK一个指标医院要900多 ...

9 l( U9 p: z; W! r$ ^, Q- S9 V平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?* N" C  J  ~) Z4 j
& I. j* |- \. A+ m5 o! A; `
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表